Compare Moderna, Inc. (MRNA) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: Moderna, Inc. is far larger — about 140.4× Direxion Daily FTSE China Bull 3x Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| MRNA | YINN | |
|---|---|---|
Market Cap | $78.65B | $560.32M |
Volume | 37,373,437 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $225.00 | $52.69 |
52-Week Low | $22.36 | $21.45 |
Typical Hold Time | 59 Days | 25 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
YINN trades at $23.63, up 0.3% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. Moving averages indicate strong bearish momentum while oscillators remain neutral. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific fundamentals show limited available data.
The bearish technical setup and lack of clear fundamental metrics create uncertainty. Investment opportunity depends on broader market trends and China's economic developments, while risks include technical breakdown below support and regional economic volatility. Further fundamental disclosure is needed for comprehensive analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
